Blog
The 2021 German Federal Election: What is the Future Outlook for Healthcare in Germany?
Published September 30, 2021
Written by Caspar Kengeter and Manon Ricard…
Webinars
Navigating the Early Asset Evaluation Journey with Confidence
February 25, 2025 | 1:00 - 1:45 PM ET
There is no room for missteps along the journey to evaluate the viability of assets in early stages of development. When making go/no go decisions, many critical questions must be answered across the early asset lifecycle. Join a team of cross-functional experts for a lively panel discussion on how to approach early commercial assessment with insight from various perspectives.
Recommended
Blog
AI-Based Software Paige Prostate is Granted FDA Approval Through the De Novo Regulatory Pathway
Published September 27, 2021
Paige Prostate is the first artificial intelligence (AI)-based software designed to identify areas of concern (i.e., high likelihood of containing cancer) on a prostate biopsy image so they can be flagged for further review by a pathologist. The program is intended to be used as an adjunct tool to the review of digital scanner slide images from prostate biopsies. The program was reviewed through the De Novo pathway, a regulatory pathway for low-to-moderate risk novel devices. The FDA authorization is based…
Blog
Part II: Non-Traditional Players Attempting Entry into the Healthcare Sector
Published September 22, 2021
Executive Summary In June 2021, Walmart announced it is partnering with Novo Nordisk to produce its own private label insulin, ReliOn, at a discount to Novo Nordisk’s currently available fast-acting insulin Through this partnership, Americans with a high-deductible health plan (HDHP) or without insurance can save up to 75% and purchase the insulin at their local Walmart Novo Nordisk’s key competitors, Eli Lilly and Sanofi are likely to respond with a similar partnership or price-cut for their insulin to remain…
Webinars
Everything You Wanted to Know About Patient Finding but Were Afraid to Ask
Available On Demand
According to a TGaS Advisors’ large landscape study, 45% of all machine learning commercial use cases in the life sciences industry were for finding patients, often for HCP alerts and targeting. In fact, if you are not doing patient finding alerts/targeting, you are probably behind the industry.Come join TGaS Advisors, a division of Trinity Life Sciences, as we share the “ins and outs” of patient finding, including learnings from our study. It’s clear that patient finding can have a big…
Blog
Part I: Non-Traditional Players Attempting Entry Into the Healthcare Sector
Published September 8, 2021
Executive Summary The healthcare sector is becoming increasingly attractive, and despite the risk of an expensive failed venture, non-traditional players have and will likely continue to take their chances to enter the field While the market has been profitable for some players such as Fujifilm and Nestlé, others have had a challenging time competing in this uniquely complex market (e.g., Kodak and Heaven) Trinity’s take: Non-traditional players that have been successful in tapping into the healthcare sector seem to follow a…
Blog
Exploring the Impact of COVID-Driven Trends on the US Healthcare Landscape
Published September 1, 2021
Executive Summary The COVID-19 pandemic has called into question many elements of the US healthcare system across key stakeholders, resulting in changes across patients, providers, payers, researchers, and manufacturers The pandemic has required many healthcare providers and patients to provide telemedicine options, which for many specialties has proved to be an effective way to dispense and receive care For payers at the national level, CMS has implemented reimbursable telehealth codes for all medical services that may be provided remotely, while…
Blog
Verily to Acquire SignalPath, Expanding the Company’s Clinical Research Capabilities
Published August 30, 2021
Verily recently announced its first major acquisition, a software platform known as SignalPath. SignalPath’s flagship software, TrialPath, digitizes and modulates individual protocols in a clinical trial, from budgeting to tracking point-of-care communication. The acquisition would fold SignalPath into Baseline, Verily’s clinical research platform designed to improve clinical trial execution, help research manage their clinical trials, and explore flexible study options for decentralized and hybrids trials as well as novel ways to capture real-world data (i.e., generated by novel sensors and biomarkers). While…
Case Studies
Global Value Messaging and P&MA Strategy for a CAR-T Cell Therapy
Trinity completed an engagement to support the successful launch of a CAR-T cell therapy with distinct clinical profile in a competitive landscape. Geographic Scope: Client Situation The client asked Trinity to develop and externally validate global payer value messages and the associated evidence set for their CAR T cell therapy. They also required support with developing a robust global pricing and market access strategy for their asset. Trinity’s Solution Trinity conducted focus groups and In-Depth-Interviews (IDIs) with key payer and provider stakeholders in scope markets to understand…
Case Studies
Assessment of the Impact of National Guidelines on Uptake of a Biomarker Among HCPs and Payers
Trinity designed staggered quantitative research to assess the impact of national guidelines on uptake of a biomarker among HCPs and payers. Geographic Scope: Client Situation The client wanted to understand the impact of national physician society guidelines on uptake / acceptance of an innovative biomarker based on developed patient vignettes, and expectations for updates to payer diagnostic testing polices. Trinity’s Solution Trinity conducted qualitative research, fielding a survey with physicians and payers, to determine current physician utilization and payer coverage of biomarker diagnostic test and track evolution in payer policies and…
Case Studies
Early P&MA Forecasting Support for a Pipeline Asset
Trinity provided early P&MA forecasting support for a pipeline asset in development for several inflammatory conditions via secondary research. Geographic Scope: Client Situation The client wanted to uncover the optimal launch strategy for their pipeline asset by understanding the current and future landscape across several inflammatory diseases to support indication prioritization. Trinity’s Solution Trinity conducted secondary research into the clinical treatment algorithms and current pricing and market access (P&MA) landscape of 19 inflammatory diseases to understand the unmet need, level of competition, payer management, contracting…